## WST: West Pharmaceutical Services, I - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 2.0% below STRENGTH zone (3.0-6.0%); PEG 3.43 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($267.55)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 4, Bearish: 0)

**1. West Pharmaceutical Services Wins Product Launch Award for Its West Synchrony S1 Prefillable Syringe System**
- Source: Pharmaceutical Technology | 20251201T072254 | Bullish | Relevance: 99%
- West Pharmaceutical Services has won the Product Launches award for its West Synchronyâ„¢ prefillable syringe (PFS) system in the 2025 Pharmaceutical Technology Excellence Awards. The award recognizes the company's integrated, data-driven syringe platform that simplifies development, strengthens supply reliability, and supports the complex requirements of biologics and vaccines. The Synchrony S1 PFS system is designed to streamline regulatory submissions and provide a reliable supply chain by offering a fully verified, system-level platform that moves beyond a component-by-component approach.

**2. 3 Reasons WST is Risky and 1 Stock to Buy Instead**
- Source: Finviz | 20251203T230100 | Neutral | Relevance: 98%
-  This article outlines three reasons to be cautious about investing in West Pharmaceutical Services (WST): lackluster revenue growth, a shrinking adjusted operating margin, and declining return on invested capital (ROIC). Despite recent stock performance, the company's business quality is deemed to fall short of analyst standards, leading to a recommendation to look for better opportunities elsewhere, particularly in favored semiconductor stocks and the author's list of high-quality momentum stocks.

**3. JPMorgan Chase & Co. Sells 435,132 Shares of West Pharmaceutical Services, Inc. $WST**
- Source: MarketBeat | 20251203T000851 | Somewhat-Bullish | Relevance: 98%
- JPMorgan Chase & Co. significantly reduced its stake in West Pharmaceutical Services, Inc. by selling 435,132 shares in Q2 2025, now holding 220,044 shares valued at $48.15 million. Despite JPMorgan's reduction, other institutional investors like Swiss National Bank and Artisan Partners increased their positions, bringing total institutional ownership to 93.9%. West Pharmaceutical Services outperformed Q3 EPS expectations, provided strong FY2025 guidance, and maintains a "Moderate Buy" consensus analyst rating with an average target price of $349.20.

**4. Morgan Stanley Initiates West Pharmaceutical Services at Equalweight With $285 Price Target**
- Source: MarketScreener | 20251202T104400 | Somewhat-Bullish | Relevance: 98%
- Morgan Stanley has initiated coverage of West Pharmaceutical Services with an Equalweight rating and a $285 price target. This initiation comes amidst a series of other analyst adjustments and company presentations scheduled for late 2025. West Pharmaceutical Services specializes in components and systems for injectable drugs, with strong sales in the United States and Europe.

**5. West Pharmaceutical Services (WST): Evaluating Valuation After Recent Momentum Shift**
- Source: Sahm | 20251201T230827 | Neutral | Relevance: 98%
-  West Pharmaceutical Services (WST) has seen a recent dip in stock movement despite a strong pharmaceutical sector, with a one-year shareholder return of -13.8% and a 13.8% gain in the last 90 days. While analysts consider it 21% undervalued with a fair value of $350.77 based on growth in GLP-1s and operational efficiencies, its price-to-earnings ratio of 40.6x is above industry averages, suggesting potential valuation risk. Investors are evaluating whether the stock is undervalued or if its current price accurately reflects future prospects.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-02 | Morgan Stanley | $285 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-02 | Morgan Stanley | init | Equal-Weight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 1 ($0.01M) |
| Sells | 0 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 46.9% |
| Smart Money | **BEARISH** |
| Net Flow | 0.0% |
| Buying/Selling | 3 / 7 |

**Top Holders:**
- Vanguard Group Inc: 13.5% (+4.2%)
- Blackrock Inc.: 9.0% (-2.3%)
- State Street Corpora: 4.5% (-1.9%)
- Bank Of New York Mel: 4.0% (-9.4%)
- Artisan Partners Lim: 3.9% (+22.2%)

### Key Risks

1. Valuation stretched: PEG 3.4x requires aggressive growth execution.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- New product launch cycle could drive revenue acceleration.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 3.43 signals overvaluation risk, limited margin of safety. Forward P/E 36.5x stretched relative to 10% growth. Quality metrics strong (ROA 10%, margin 16%). Balance sheet: strong liquidity (2.9x), low leverage (D/E 0.35). Institutional flow bearish (7 selling vs 3 buying).

| Metric | Value |
|--------|-------|
| Market Cap | $19.1B |
| Beta | 1.17 |
| 52W Range | $187.43 - $348.90 |
| Short Interest | 3.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 3.43 |
| Forward P/E | 36.5 |
| Current P/E | 40.0 |
| YoY Growth | 9.6% |
| EPS Direction | RISING |

### Technicals

MRS_10 improving modestly (+0.5% over 5 days). Below STRENGTH zone by 1.0pp (needs >3.0% for momentum thesis). MRS_5 at 2.1% confirms short-term momentum alignment. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram positive (1.23), confirming momentum. RSI neutral at 59.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 2.02% (CS: 75) | Neutral |
| RSI_14 | 59.4 | Neutral |
| MACD Histogram | 1.23 | Bullish |
| vs SMA20 | 1.046x | Above |
| vs SMA50 | 1.044x | Above |
| vs SMA200 | 1.193x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $284.31
- **Stop Loss:** $267.55 (5.9% risk)
- **Target:** $301.07 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 56
- **Position Value:** $15,921.36
- **Portfolio %:** 15.92%
- **Risk Dollars:** $950.00
- **Risk Per Trade:** 0.95%
- **Modifiers:** L1 95% | L2 100% | Combined 0.95x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 0.95x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate risk appetite. VIX at 16 is below median, showing calm, but breadth is only moderate and put/call is neutral, suggesting neither strong bullish nor defensive extremes. Key drivers are rising Fed rate-cut odds from soft ADP jobs data, mixed earnings across sectors, and ongoing AI/tech strength offset by caution in cyclicals and banks. Positioning should remain selective and neutral, awaiting more decisive macro or earnings signals.*

### Earnings

**Next:** 2026-02-12 (Est: $1.83)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.71 | $1.96 | +14.5% |
| 2025Q2 | $1.54 | $1.84 | +19.7% |
| 2025Q1 | $1.26 | $1.45 | +15.3% |
| 2024Q4 | $1.73 | $1.82 | +5.3% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*